focus -WSS

focus

author：hotspot 2025-08-19 20:47:31 - browse：44293

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

hotspot

WSS

Elisabeth Bik tackles the widespread issue of research misconduct

Hospital price transparency does save money, advocate argues

The explosion of genetic testing requires a new approach

Medicare isn't yet testing food as medicine

Researchers explore possible ties between long Covid, menopause

Eli Lilly expects to double planned employment in Boston center

Wikipedia

focus

leisure time

How to save PrEP access — and even expand it

Study fuels hope CAR

Bright Health sells Medicare Advantage business to Molina

Studies point to risks of excluding people with obesity from drug trials

Novavax promises a turnaround & Lilly roils the obesity market

Laying a path for careers in science

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Researchers explore possible ties between long Covid, menopause

In age of alternative facts, a scholarly course on calling out crap

Impact of Dobbs ruling felt at reproductive medicine meeting

focus

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

FDA gives detailed accounting of AI

Childhood vaccination ad campaign launches in the U.K.

HHS leader on health, climate change and biopharma emissions

STAT Madness 2024: Meet the contenders

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

hotspot

focus

hotspot

hotspot